How to Improve Prognostication in Acute Myeloid Leukemia with <i>CBFB-MYH11</i> Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring

How to Improve Prognostication in Acute Myeloid Leukemia with <i>CBFB-MYH11</i> Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring

Acute myeloid leukemia (AML) carrying inv(16)/t(16;16), resulting in fusion transcript <i>CBFB-MYH11</i>, belongs to the favorable-risk category. However, even if most patients obtain morphological complete remission after induction, approximately 30% of cases eventually relapse. While w...

Full description

Bibliographic Details
Main Authors: Annalisa Talami, Francesca Bettelli, Valeria Pioli, Davide Giusti, Andrea Gilioli, Corrado Colasante, Laura Galassi, Rachele Giubbolini, Hillary Catellani, Francesca Donatelli, Rossana Maffei, Silvia Martinelli, Patrizia Barozzi, Leonardo Potenza, Roberto Marasca, Tommaso Trenti, Enrico Tagliafico, Patrizia Comoli, Mario Luppi, Fabio Forghieri
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Biomedicines
Subjects:
acute myeloid leukemia
<i>CBF</i><i>B-MYH11</i> fusion transcript
molecular measurable residual disease monitoring
prognostic thresholds and timepoints
intensive chemotherapy
clinical outcomes
Online Access:https://www.mdpi.com/2227-9059/9/8/953

Internet

https://www.mdpi.com/2227-9059/9/8/953

Similar Items